Satellite Bio Analysis: $110M Raised
What is Satellite Bio?
First-of-its-kind SAT platform turns any cell into bioengineered tissue for organ repair
Location
Cambridge, United States
Employees
11-50
Founded
2019
Product Features & Capabilities
- SAT Platform enabling expansion, seed formation and stabilization of solid organ cells
- Tissue Therapeutics for liver function restoration
- Expandable hepatocyte cell therapy for organ repair
Use Cases
Restore liver function in patients with genetic and environmental disease interactions; Deliver tailored therapies for severe, life-threatening conditions; Enable durable engraftment of expanded hepatocyte cells; Treat diseases requiring cellular repair or organ replacement
Other Considerations
Published first preprint on expandable hepatocyte technology in bioRxiv; CEO presented at Med 2024 Cell & Gene Meeting; Co-Founders include Sangeeta Bhatia, MD, PhD and Christopher Chen, MD, PhD; Based in Cambridge, MA; Founded in 2019; Employee count: 11-50
See something that needs updating? Suggest edits to this profile.